 | |
| Combination of | |
|---|---|
| Indacaterol | Ultra-long-acting beta-adrenoceptor agonist |
| Glycopyrronium bromide | Muscarinicanticholinergic |
| Clinical data | |
| Trade names | Ultibro Breezhaler, Utibron Neohaler, Xoterna Breezhaler |
| Pregnancy category |
|
| Routes of administration | Inhalation only |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChemCID | |
| KEGG | |
| CompTox Dashboard(EPA) | |
Indacaterol/glycopyrronium bromide, sold under the brand nameUltibro Breezhaler among others, is a fixed-dosecombination medication for inhalation consisting of the following two active ingredients:
Indacaterol maleate/glycopyrronium bromide is used as a maintenance bronchodilator treatment to relieve symptoms in adult patients withchronic obstructive pulmonary disease (COPD).[3]
The drug is marketed byNovartis under the trade names Ultibro Breezhaler and Utibron Neohaler in Europe and the United States, respectively.[3][4] In 2016, Novartis licensed its U.S. commercial rights for Seebri Neohaler and Utibron Neohaler to Sunovion Pharmaceuticals.[5]
 | Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it. |
